ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print

Stockpiling iPS cells brings treatment one step closer

Time, costs can be trimmed, but risk of rejection remains

Researchers perform the world's first transplant using donor-derived iPS cells at Kobe City Medical Center General Hospital.

TOKYO Japanese researchers performed the world's first transplant of retina cells made from donor-derived induced pluripotent stem (iPS) cells into a patient's eye in late March. Compared with using the patient's own cells to create the iPS cells, the cost and time needed to prepare for surgery can be reduced to less than one tenth.

The clinical study on March 28 was conducted by a team involving the government-affiliated research institute Riken, Kobe City Medical Center General Hospital, Kyoto University and other entities.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more